Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mirum Pharmaceuticals (MIRM) Accounts Payables (2020 - 2025)

Mirum Pharmaceuticals (MIRM) has 6 years of Accounts Payables data on record, last reported at $9.6 million in Q4 2025.

  • For Q4 2025, Accounts Payables fell 34.23% year-over-year to $9.6 million; the TTM value through Dec 2025 reached $9.6 million, down 34.23%, while the annual FY2025 figure was $9.6 million, 34.23% down from the prior year.
  • Accounts Payables reached $9.6 million in Q4 2025 per MIRM's latest filing, down from $12.2 million in the prior quarter.
  • Across five years, Accounts Payables topped out at $17.7 million in Q2 2025 and bottomed at $4.9 million in Q1 2022.
  • Average Accounts Payables over 5 years is $9.7 million, with a median of $9.4 million recorded in 2021.
  • Peak YoY movement for Accounts Payables: soared 190.89% in 2021, then plummeted 34.23% in 2025.
  • A 5-year view of Accounts Payables shows it stood at $9.2 million in 2021, then dropped by 5.19% to $8.7 million in 2022, then fell by 14.66% to $7.4 million in 2023, then surged by 97.11% to $14.6 million in 2024, then tumbled by 34.23% to $9.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Accounts Payables were $9.6 million in Q4 2025, $12.2 million in Q3 2025, and $17.7 million in Q2 2025.